Skip to main content

Advertisement

Table 1 Patient´s characteristics and HER2 positivity by subgroups

From: The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing

  Total n=96 (%) Positivity* (IHC 3+ or SISH +) single n(%) Positivity* (IHC 3+ or SISH +) combi n(%)
Sex    
Female 27 (28.1) 2 (7.4) 1 (3.7)
Male 65 (67.7) 11 (16.9) 11 (16.9)
Unknown 4 (4.2) 3 (75.0) 3 (75.0)
Age 18-94 yrs (Median 69)   
≥ 65 68 (70.8) 12 (17.6) 11 (16.2)
< 65 28 (29.2) 4 (14.3) 4 (14.3)
Primary tumor location    
Mid to distal stomach 48 (50.0) 5 (10.4) 4 (8.3)
GEJ 44 (45.8) 8 (18.2) 8 (18.2)
Not specified 4 (4.2) 3 (75.0) 3 (75.0)
Lauren classification    
Diffuse 27 (28.1) 3 (11.1) 2 (7.4)
Mixed 4 (4.2) 1 (25.0) 1 (25.0)
Intestinal 65 (67.7) 12 (18.5) 12 (18.5)
Biopsy/resection    
Biopsy 68 (70.8) 10 (14.7) 9 (13.2)
Resection 28 (29.2) 6 (21.4) 6 (21.4)
T stage ( n =28)    
T 1 4 (14.3) 0 0
T 2 8 (28.6) 2 (25.0) 2 (25.0)
T 3 14 (50.0) 4 (28.6) 4 (28.6)
T 4 2 (7.1) 0 0
N stage ( n =28)    
N + 24 (85.7) 5 (20.8) 5 (28.8)
N - 4 (14.3) 1 (25.0) 1 (25.0)
M stage ( n =28)    
M + 5 (17.9) 1 (20.0) 1 (20.0)
M - 18 (64.3) 3 (16.7) 3 (16.7)
Mx 5 (17.9) 2 (40.0) 2 (40.0)
Grading    
G2 38 (39.6) 6 (15.8) 6 (15.8)
G2-3 10 (10.4) 2 (20.0) 2 (20.0)
G3 48 (50.0) 8 (16.7) 7 (14.6)
  1. Abbreviations: IHC immunohistochemistry, SISH silver in situ hybridization T primary tumor, N lymph nodes, M metastases *defined as IHC 3+ or SISH ≥2.0.
  2. P=1 for all comparisons between IHC/SISH and gene/protein methods (Fisher´s Exact Test).